Literature DB >> 2264343

[Steroid receptors and atypical histology as prognostic parameters in meningioma].

H Kostron1, G Daxenbichler, H Maier.   

Abstract

Cytosolic oestrogen and progesterone receptors (ER and PR) were determined in 58 primary and 13 recurrent meningiomas and related to their histological and clinical features. ER levels were low or not detectable (range 0-34 fmol/mg prot., median 0 fmol), whereas considerable amounts of PR were found in 69% of primary tumours (range 0-583 fmol/mg prot., median 72 fmol) and in 5/5 long-term recurrences (range 69-505 fmol/mg prot., median 143). Eight tumours recurred within a short-term period (less than 5 years) with a low PR expression (range 0-34 fmol/mg prot., median 0 fmol) and all presented raised cellularity and mitotic rate ("atypical" meningioma) or criteria of definitely malignant meningioma. The primary tumours of the short-term recurrences were not available for receptor analysis; however, they also were either "atypical" or anaplastic meningiomas. Long-term recurrences never displayed other than classical histology. From our results we conclude that polymorphy, as well as a lack of PR are strong indicators for short-term recurrence.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2264343

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  2 in total

1.  Iatrogenic metastasis of a benign meningioma to the periosteum at the site of previous craniotomy: a case report.

Authors:  Tomaz Velnar; Gorazd Bunc
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

2.  Progesterone-receptor index in meningiomas: correlation with clinico-pathological parameters and review of the literature.

Authors:  Stefan Wolfsberger; Soroush Doostkam; Hans-Gerd Boecher-Schwarz; Karl Roessler; Michael van Trotsenburg; Johannes A Hainfellner; Engelbert Knosp
Journal:  Neurosurg Rev       Date:  2004-05-27       Impact factor: 3.042

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.